GlassScriptPhysician profile
Brooks Ryan Crowe
NPI 1174979272
$1,934.51
in general payments reported to CMS, 2019-2025
18 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $353 · 2023: $1,220 · 2024: $94.77 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.89 | 2022-2025 | Skyrizi, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.48 | 2022-2023 | Xifaxan |
| Celgene Corporation | $197.29 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $171.91 | 2022-2025 | |
| Janssen Biotech, INC. | $137.63 | 2022-2025 | Stelara, Remicade, Simponi |
| Madrigal Pharmaceuticals | $130.23 | 2025 | Rezdiffra |
| Fresenius Kabi USA, LLC | $125.10 | 2023 | Idacio |
| Ardelyx, INC. | $97.15 | 2023 | Ibsrela |
| Exact Sciences Corporation | $55.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Intercept Pharmaceuticals, INC. | $52.53 | 2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $45.94 | 2023 | Linzess |
| Coloplast Corp | $32.93 | 2025 | |
| Genzyme Corporation | $24.29 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.80 | 2023 | Entyvio |
| Redhill Biopharma INC. | $21.67 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $20.78 | 2022 | |
| Capsovision, INC. | $19.10 | 2024 | Capsocam Plus |
| Evoke Pharma, INC. | $15.94 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.